January 10, 2022 -- 2seventy bio has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. The agreement builds on a successful existing multiyear research collaboration between the two companies.
Under the terms of the agreement, Novo Nordisk will have the option to license 2seventy bio's proprietary mRNA-based megaTAL technology for the development of a new treatment approach for hemophilia A, with the goal of offering a sustained therapeutic effect in patients. The agreement with Novo Nordisk builds on a research collaboration agreement signed between Bluebird Bio and Novo Nordisk in 2019, which is focused on identifying a gene therapy candidate for people with hemophilia A.
The collaboration utilizes 2seventy bio's megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit, or insert genetic components, according to the companies. Hemophilia A is a genetic bleeding disorder resulting from defective factor VIII.
2seventy bio will receive an upfront payment of $5 million and is eligible for near-term milestone and option exercise payments of up to $35 million. In addition, the company is eligible to receive development, regulatory, and commercial milestone payments, as well as a royalty on net sales. Novo Nordisk will be responsible for funding all R&D activities.